CA2495830A1 - The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis - Google Patents
The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis Download PDFInfo
- Publication number
- CA2495830A1 CA2495830A1 CA002495830A CA2495830A CA2495830A1 CA 2495830 A1 CA2495830 A1 CA 2495830A1 CA 002495830 A CA002495830 A CA 002495830A CA 2495830 A CA2495830 A CA 2495830A CA 2495830 A1 CA2495830 A1 CA 2495830A1
- Authority
- CA
- Canada
- Prior art keywords
- inn
- pharmaceutical composition
- application
- methyl
- ciclesonide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 title claims abstract 10
- 229960003728 ciclesonide Drugs 0.000 title claims abstract 9
- 239000000739 antihistaminic agent Substances 0.000 title claims abstract 7
- 206010039085 Rhinitis allergic Diseases 0.000 title claims 5
- 201000010105 allergic rhinitis Diseases 0.000 title claims 5
- 238000011282 treatment Methods 0.000 title claims 5
- 229940125715 antihistaminic agent Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 210000004877 mucosa Anatomy 0.000 claims 14
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 230000003204 osmotic effect Effects 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 230000001387 anti-histamine Effects 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- SFOVDSLXFUGAIV-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1=CC(F)=CC=C1CN1C2=CC=CC=C2N=C1NC1CCNCC1 SFOVDSLXFUGAIV-UHFFFAOYSA-N 0.000 claims 4
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 3
- BAWMMJAUVBLLEE-UHFFFAOYSA-N 2-[2-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 BAWMMJAUVBLLEE-UHFFFAOYSA-N 0.000 claims 2
- DIGXMFZQXQUVMR-UHFFFAOYSA-N 5-hexyl-7-(methylsulfonimidoyl)-9-oxoxanthene-2-carboxylic acid Chemical compound O1C2=CC=C(C(O)=O)C=C2C(=O)C2=C1C(CCCCCC)=CC(S(C)(=N)=O)=C2 DIGXMFZQXQUVMR-UHFFFAOYSA-N 0.000 claims 2
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 claims 2
- 229960004574 azelastine Drugs 0.000 claims 2
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 235000010980 cellulose Nutrition 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 claims 2
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 claims 2
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 229960001120 levocabastine Drugs 0.000 claims 2
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 claims 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- HIANJWSAHKJQTH-UHFFFAOYSA-N pemirolast Chemical compound CC1=CC=CN(C2=O)C1=NC=C2C=1N=NNN=1 HIANJWSAHKJQTH-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- WUZYKBABMWJHDL-UHFFFAOYSA-N rupatadine Chemical compound CC1=CN=CC(CN2CCC(CC2)=C2C3=NC=CC=C3CCC3=CC(Cl)=CC=C32)=C1 WUZYKBABMWJHDL-UHFFFAOYSA-N 0.000 claims 2
- VBSPHZOBAOWFCL-UHFFFAOYSA-N setastine Chemical compound C=1C=CC=CC=1C(C=1C=CC(Cl)=CC=1)(C)OCCN1CCCCCC1 VBSPHZOBAOWFCL-UHFFFAOYSA-N 0.000 claims 2
- 229920003169 water-soluble polymer Polymers 0.000 claims 2
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims 1
- YNNUSGIPVFPVBX-UHFFFAOYSA-N 2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound CN1CCCC1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-UHFFFAOYSA-N 0.000 claims 1
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 claims 1
- CWNCDQYLHMXURI-UHFFFAOYSA-N 3-[4-(8-fluoro-5h-[1]benzoxepino[4,3-b]pyridin-11-ylidene)piperidin-1-yl]propanoic acid;dihydrate Chemical compound O.O.C1CN(CCC(=O)O)CCC1=C1C2=NC=CC=C2COC2=CC(F)=CC=C21 CWNCDQYLHMXURI-UHFFFAOYSA-N 0.000 claims 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 claims 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229960003792 acrivastine Drugs 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 229960000383 azatadine Drugs 0.000 claims 1
- 229960002071 bepotastine Drugs 0.000 claims 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims 1
- 229960001803 cetirizine Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims 1
- 229960002881 clemastine Drugs 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 229960001271 desloratadine Drugs 0.000 claims 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 claims 1
- 229960001882 dexchlorpheniramine Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960001971 ebastine Drugs 0.000 claims 1
- 229950003420 efletirizine Drugs 0.000 claims 1
- 229960000325 emedastine Drugs 0.000 claims 1
- 229960003449 epinastine Drugs 0.000 claims 1
- 229960003592 fexofenadine Drugs 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 229960001508 levocetirizine Drugs 0.000 claims 1
- 229960003088 loratadine Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960001144 mizolastine Drugs 0.000 claims 1
- 210000002850 nasal mucosa Anatomy 0.000 claims 1
- 229960001158 nortriptyline Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229960004439 pemirolast Drugs 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 229960005328 rupatadine Drugs 0.000 claims 1
- 229950003911 setastine Drugs 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229950001539 sudexanox Drugs 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 229950008068 tecastemizole Drugs 0.000 claims 1
- 229960000351 terfenadine Drugs 0.000 claims 1
- 229960003223 tripelennamine Drugs 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a combination of ciclesonide with antihistamines.
Claims (18)
1. Pharmaceutical composition for the treatment of allergic rhinitis and/or allergic conjunctivitis com-prising as active ingredients a combination of at least one antihistamine, a stereoisomer, a Pharma-ceutically acceptable salt, solvate or physiologically functional derivative thereof and ciclesonide, pharmaceutically acceptable salts of ciclesonide, epimers of ciclesonide optionally in any mixing ra-tio with ciclesonide, solvates of ciclesonide, physiologically functional derivatives of ciclesonide or solvates thereof and a pharmaceutically acceptable carrier and/or one or more excipients.
2. Pharmaceutical composition according to claim 1 for the treatment of allergic rhinitis for application to the mucosa, which is an aqueous pharmaceutical composition comprising the active ingredients together with one or more water-insoluble and/or water-low soluble substance and having an osmo-tic pressure of less than 290 mOsm.
3. The pharmaceutical composition for application to the mucosa according to claim 2, wherein said osmotic pressure is 150 mOsm or less.
4. The pharmaceutical composition for application to the mucosa according to claim 2, wherein said osmotic pressure is 60 mOsm or less.
5. The pharmaceutical composition for application to the mucosa according to claim 2, wherein said osmotic pressure is 40 mOsm or less.
6. The pharmaceutical composition for application to the mucosa according to claim 2, wherein said osmotic pressure is 20 mOsm or less.
7. The pharmaceutical composition for application to the mucosa according to claim 2, further com-prising an osmotic pressure-controlling agent.
8. The pharmaceutical composition for application to the mucosa according to claim 2, wherein said water-insoluble and/or water-low soluble substance is a cellulose.
9. The pharmaceutical composition for application to the mucosa according to claim 8, wherein said cellulose is microcrystalline cellulose.
10. The pharmaceutical composition for application to the mucosa according to claim 2, wherein said one or more water-insoluble and/or water-low soluble substance is present as solid particles in an aqueous medium.
11. The pharmaceutical composition for application to the mucosa according to claim 2, further com-prising a water-soluble polymer substance.
12. Pharmaceutical composition for application to the mucosa according to claim 11, wherein a combi-nation of said water-insoluble substance and water-soluble polymer is present which is microcrys-talline cellulose and carboxymethyl cellulose sodium.
13. The pharmaceutical composition for application to the mucosa according to claim 2, further com-prising a surfactant and/or a wetting agent.
14. The pharmaceutical composition for application to the mucosa according to claim 2, wherein said mucosa is nasal mucosa.
15. Pharmaceutical composition according to claims 1 through 14, wherein the antihistamine is se-lected from the group of (E)-6-[(E)-3-(1-pyrrolidinyl)-1-p-tolylpropenyl]-2-pyridineacrylic acid [INN:
ACRIVASTINE], 6,11-Dihydro-11-(1-methyl-4-piperidyliden)-5H-benzo[5,6]cyclohepta-[1,2-b]pyridin [INN: AZATADINE], 4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)phthal-azinone [INN: AZELASTINE], (+)-(S)-4-[4-[1-(4-chlorophenyl)-1-(2-pyridyl)methoxy]piperidin-1-yl]-butanoic acid [INN: BEPOTASTINE], (plus/minus)-[2-[4-(p-chloro-alpha-phenylbenzyl)-1-piperazi-nyl]ethoxy]-acetic acid [INN: CETIRIZINE], (+)-2-{2-[(p-Chlor-alpha-methyl-alpha phenylbenzyl)oxy]-ethyl}-1-methylpyrrolidin [INN: CLEMASTINE], 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta-[1,2-b]pyridine [INN: DESLORATADINE], [3-(4-Chlorophenyl)-3-pyridin-2-yl-propyl]-dimethylamine [INN: DEXCHLORPHENIRAMINE], 4'-tert-butyl-4-[4-(diphenylmethoxy)-piperidino]butyrophenone [INN: EBASTINE], [2-[4-[bis(p-fluorophenyl)methyl]-1-piperazinyl]ethoxy]-acetic acid [INN: EFLETIRIZINE], 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-benzimidazole [INN: EMEDASTINE], 3-amino-9,13b-dihydro-1H-dibenz[c,f]imidazo[1,5-a]azepine [INN: EPINASTINE], (plus/minus)-p-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidino]-butyl]-alpha-methylhydratropic acid [INN: FEXOFENADINE], 3-[4-(8-fluoro-5,11-dihydrobenz[b]oxe-pino[4,3-b]pyridin-11-ylidene)-piperidin-1-yl]propionic acid [Research Code:
HSR-609], (-)-(3S,4R)-1-[cis-4-cyano-4-(p-fluorophenyl)cyclohexyl]-3-methyl-4-phenylisonipecotic acid [INN: LEVOCA-BASTINE], [2-[4-[(R)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl]ethoxy]-acetic acid [INN: LEVO-CETIRIZINE], ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate [INN: LORATADINE], 2-[N-[1-(4-fluorobenzyl)-1H-benzimidazol-2-yl]-4-piper-idinyl]-N-methyl-amino]pyrimidin-4(3H)-one [INN: MIZOLASTINE], 1-(4-fluorobenzyl)-2-(piperidin-4-ylamino)-1 H-benzimidazole [INN: NORASTEMIZOLE], 3-(10,11-dihydro-5H-dibenzo[a,d]cyclo-hepten-5-ylidene)-N-methyl-1-propanamine [INN: NORTRIPTYLINE], 9-methyl-3-(1 H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one [INN: PEMIROLAST], 8-chloro-11-[1-(5-methylpyridin-3-ylmethyl)-piperidin-4-ylidene]-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine [INN:
RUPATADINE], 1-[2-[(p-chloro-alpha-methyl-alpha-phenylbenzyl)oxy]ethyl]hexahydro-1 H-azepine [INN: SETASTINE], S-(7-carboxy-4-hexyl-9-oxoxanthen-2-yl)-S-methylsulfoximine [INN: SUDEXANOX], 1-(p-tert-butyl-phenyl)-4-[4'-(alpha-hydroxydiphenylmethyl)-1'-piperidyl]-butanol [INN:
TERFENADINE], N-benzyl-N,N'-dimethyl-N-(2-pyridyl)-ethylenediamine [INN: TRIPELENAMINE] and 1-(4-fluorobenzyl)-2-(piperidin-4-ylamino)-1H-benzimidazole [INN: TECASTEMIZOLE] and mixtures, stereoisomers thereof, pharmaceutically acceptable salts and/or solvates thereof.
ACRIVASTINE], 6,11-Dihydro-11-(1-methyl-4-piperidyliden)-5H-benzo[5,6]cyclohepta-[1,2-b]pyridin [INN: AZATADINE], 4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)phthal-azinone [INN: AZELASTINE], (+)-(S)-4-[4-[1-(4-chlorophenyl)-1-(2-pyridyl)methoxy]piperidin-1-yl]-butanoic acid [INN: BEPOTASTINE], (plus/minus)-[2-[4-(p-chloro-alpha-phenylbenzyl)-1-piperazi-nyl]ethoxy]-acetic acid [INN: CETIRIZINE], (+)-2-{2-[(p-Chlor-alpha-methyl-alpha phenylbenzyl)oxy]-ethyl}-1-methylpyrrolidin [INN: CLEMASTINE], 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta-[1,2-b]pyridine [INN: DESLORATADINE], [3-(4-Chlorophenyl)-3-pyridin-2-yl-propyl]-dimethylamine [INN: DEXCHLORPHENIRAMINE], 4'-tert-butyl-4-[4-(diphenylmethoxy)-piperidino]butyrophenone [INN: EBASTINE], [2-[4-[bis(p-fluorophenyl)methyl]-1-piperazinyl]ethoxy]-acetic acid [INN: EFLETIRIZINE], 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-benzimidazole [INN: EMEDASTINE], 3-amino-9,13b-dihydro-1H-dibenz[c,f]imidazo[1,5-a]azepine [INN: EPINASTINE], (plus/minus)-p-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidino]-butyl]-alpha-methylhydratropic acid [INN: FEXOFENADINE], 3-[4-(8-fluoro-5,11-dihydrobenz[b]oxe-pino[4,3-b]pyridin-11-ylidene)-piperidin-1-yl]propionic acid [Research Code:
HSR-609], (-)-(3S,4R)-1-[cis-4-cyano-4-(p-fluorophenyl)cyclohexyl]-3-methyl-4-phenylisonipecotic acid [INN: LEVOCA-BASTINE], [2-[4-[(R)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl]ethoxy]-acetic acid [INN: LEVO-CETIRIZINE], ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate [INN: LORATADINE], 2-[N-[1-(4-fluorobenzyl)-1H-benzimidazol-2-yl]-4-piper-idinyl]-N-methyl-amino]pyrimidin-4(3H)-one [INN: MIZOLASTINE], 1-(4-fluorobenzyl)-2-(piperidin-4-ylamino)-1 H-benzimidazole [INN: NORASTEMIZOLE], 3-(10,11-dihydro-5H-dibenzo[a,d]cyclo-hepten-5-ylidene)-N-methyl-1-propanamine [INN: NORTRIPTYLINE], 9-methyl-3-(1 H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one [INN: PEMIROLAST], 8-chloro-11-[1-(5-methylpyridin-3-ylmethyl)-piperidin-4-ylidene]-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine [INN:
RUPATADINE], 1-[2-[(p-chloro-alpha-methyl-alpha-phenylbenzyl)oxy]ethyl]hexahydro-1 H-azepine [INN: SETASTINE], S-(7-carboxy-4-hexyl-9-oxoxanthen-2-yl)-S-methylsulfoximine [INN: SUDEXANOX], 1-(p-tert-butyl-phenyl)-4-[4'-(alpha-hydroxydiphenylmethyl)-1'-piperidyl]-butanol [INN:
TERFENADINE], N-benzyl-N,N'-dimethyl-N-(2-pyridyl)-ethylenediamine [INN: TRIPELENAMINE] and 1-(4-fluorobenzyl)-2-(piperidin-4-ylamino)-1H-benzimidazole [INN: TECASTEMIZOLE] and mixtures, stereoisomers thereof, pharmaceutically acceptable salts and/or solvates thereof.
16. Pharmaceutical composition according to claims 1 through 14, wherein the antihistamine is aze-lastine, levocabastine, a salt or solvate thereof.
17. Use of ciclesonide in combination with at least one antihistamine for the manufacture of a pharma-ceutical composition for the treatment of allergic rhinitis and/or allergic conjunctivitis.
18. Method for the prophylaxis or treatment of allergic rhinitis and/or allergic conjunctivitis in a mammal, such as a human, which comprises administration of a therapeutically effective amount of a phar-maceutical formulation comprising at least one antihistamine or a pharmaceutical acceptable salt, solvate, or physiologically functional derivative thereof and ciclesonide or a pharmaceutical accept-able salt, solvate, or physiologically functional derivative thereof, and a pharmaceutical acceptable carrier and/or one or more excipients.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02019406.4 | 2002-08-30 | ||
| EP02019406 | 2002-08-30 | ||
| PCT/EP2003/009622 WO2004019955A1 (en) | 2002-08-30 | 2003-08-29 | The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2495830A1 true CA2495830A1 (en) | 2004-03-11 |
| CA2495830C CA2495830C (en) | 2012-08-21 |
Family
ID=31970274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2495830A Expired - Fee Related CA2495830C (en) | 2002-08-30 | 2003-08-29 | The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7879832B2 (en) |
| EP (2) | EP2295062B1 (en) |
| JP (2) | JP4746318B2 (en) |
| KR (1) | KR101067795B1 (en) |
| CN (1) | CN1674916A (en) |
| AT (1) | ATE472329T1 (en) |
| AU (1) | AU2003273396B2 (en) |
| BR (2) | BR0313611A (en) |
| CA (1) | CA2495830C (en) |
| DE (1) | DE60333205D1 (en) |
| DK (1) | DK1545548T3 (en) |
| ES (2) | ES2393864T3 (en) |
| IL (1) | IL166483A (en) |
| MX (1) | MXPA05001885A (en) |
| NO (1) | NO335400B1 (en) |
| NZ (1) | NZ538954A (en) |
| PL (1) | PL373433A1 (en) |
| PT (1) | PT1545548E (en) |
| SI (1) | SI1545548T1 (en) |
| WO (1) | WO2004019955A1 (en) |
| ZA (1) | ZA200500719B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| PT1572217E (en) * | 2002-12-12 | 2008-11-28 | Nycomed Gmbh | Combination medicament of r,r-formoterol and ciclesonide |
| EP1635845A1 (en) * | 2003-06-13 | 2006-03-22 | ALTANA Pharma AG | Formoterol and ciclesonide combination |
| PE20050941A1 (en) * | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | AQUEOUS CYCLESOUND SUSPENSIONS FOR MISTING |
| PT2522365T (en) | 2004-11-24 | 2017-02-08 | Meda Pharmaceuticals Inc | Compositions comprising azelastine and methods of use thereof |
| US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
| US8758816B2 (en) | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| WO2006097458A1 (en) * | 2005-03-15 | 2006-09-21 | Nycomed Gmbh | Novel combination |
| US20080311196A1 (en) * | 2006-07-13 | 2008-12-18 | White Donna F | All Day Rhinitic Condition Treatment Regimen |
| US20080015241A1 (en) * | 2006-07-13 | 2008-01-17 | Cornerstone Biopharma, Inc. | All day rhinitic condition treatment regimen |
| JP5661985B2 (en) * | 2006-12-27 | 2015-01-28 | 帝人ファーマ株式会社 | Aseptic aqueous suspension formulation |
| KR100878698B1 (en) * | 2007-04-05 | 2009-01-13 | 한미약품 주식회사 | Crystalline hydrate of bepotastine metal salt, method for preparing same and pharmaceutical composition comprising same |
| EP2624836B1 (en) * | 2010-10-06 | 2015-09-23 | Bausch & Lomb Incorporated | Bepotastine compositions |
| WO2012094283A2 (en) * | 2011-01-04 | 2012-07-12 | Ista Pharmaceuticals, Inc. | Bepotastine compositions |
| JP6545148B2 (en) | 2013-03-13 | 2019-07-17 | フラットリー ディスカバリー ラブ，エルエルシー | Pyridazinone compounds and methods for the treatment of cystic fibrosis |
| CN106692115A (en) * | 2015-11-13 | 2017-05-24 | 天津金耀集团有限公司 | Ciclesonide suspension nasal spray composition |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL132137C (en) | 1963-04-24 | |||
| US3813384A (en) * | 1972-01-17 | 1974-05-28 | Asta Werke Ag Chem Fab | Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof |
| US4369184A (en) | 1980-01-24 | 1983-01-18 | Janssen Pharmaceutica N.V. | 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives |
| JPS6150978A (en) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | Pyridine derivative and preparation thereof |
| ES2053678T3 (en) * | 1987-11-13 | 1994-08-01 | Asta Medica Ag | PROCEDURE FOR PREPARING AN AZELASTIN CONTENT MEDICATION FOR NASAL AND / OR EYE APPLICATION. |
| GR1001529B (en) * | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Process for the obtainment of a new pregna-1,4-diene-3,20-dione -16-17-acetal-21 esters |
| CZ287877B6 (en) | 1993-04-02 | 2001-03-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Prednisolone derivatives and pharmaceutical preparation in which they are comprised |
| EP0709099A3 (en) | 1994-09-28 | 1996-07-24 | Senju Pharma Co | An aqueous nasal suspension comprising cyclodextrin |
| DE19541689A1 (en) | 1994-11-14 | 1996-05-15 | Byk Gulden Lomberg Chem Fab | Medicament contg. ciclesonid and beta2-sympathomimetic |
| WO1997001337A1 (en) | 1995-06-29 | 1997-01-16 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal steroids |
| WO1997001341A1 (en) | 1995-06-29 | 1997-01-16 | Mcneil-Ppc, Inc. | The combination of topical nasal mast cell stabilizers and topical nasal steroids |
| EP0780127A1 (en) | 1995-12-19 | 1997-06-25 | The Procter & Gamble Company | A nasal spray containing a steroid and a antihistamine |
| AU3153797A (en) | 1996-06-04 | 1998-01-05 | Procter & Gamble Company, The | A nasal spray containing an intranasal steroid and an antihistamine |
| FR2754712B1 (en) * | 1996-10-17 | 1999-09-03 | Merck Sharp Dohme Chibret Lab | OPHTHALMIC COMPOSITIONS |
| US20020111495A1 (en) * | 1997-04-04 | 2002-08-15 | Pfizer Inc. | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes |
| JP2001524108A (en) | 1997-04-30 | 2001-11-27 | ワーナー−ランバート・カンパニー | Topical nasal anti-inflammatory composition |
| EP0903151A1 (en) * | 1997-09-22 | 1999-03-24 | ASTA Medica Aktiengesellschaft | Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms |
| TWI243687B (en) * | 1998-04-21 | 2005-11-21 | Teijin Ltd | Pharmaceutical composition for application to mucosa |
| US6297227B1 (en) * | 1998-09-10 | 2001-10-02 | Schering Corporation | Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines |
| US20020061281A1 (en) * | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| DE19947234A1 (en) | 1999-09-30 | 2001-04-05 | Asta Medica Ag | New combination of loteprednol and antihistamines |
| AR026073A1 (en) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | PHARMACEUTICAL COMPOSITION AQUATIC CONTAINING CICLESONIDE |
| KR20010089887A (en) | 1999-10-20 | 2001-10-12 | 야스이 쇼사꾸 | Aqueous medicinal compositions |
| AR026072A1 (en) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | PHARMACEUTICAL COMPOSITION CONTAINING CICLESONIDE FOR MUCOSA APPLICATION |
| US20040097486A1 (en) * | 1999-11-18 | 2004-05-20 | Yanni John M. | Use of an H1 antagonist and a safe steroid to treat eye conditions |
| BR0015647A (en) | 1999-11-18 | 2002-07-16 | Alcon Inc | Use of an h1 antagonist and a safe steroid to treat eye conditions |
| US6653313B2 (en) | 2000-08-10 | 2003-11-25 | Warner-Lambert Company Llc | 1,4-dihydropyridine compounds as bradykinin antagonists |
| US6706726B2 (en) * | 2000-10-14 | 2004-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics which may be used as medicaments as well as processes for preparing them |
| WO2003049770A1 (en) | 2001-12-05 | 2003-06-19 | Alcon, Inc. | Use of an h1 antagonist and a safe steroid to treat rhinitis |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| KR20050074577A (en) * | 2002-11-12 | 2005-07-18 | 알콘, 인코퍼레이티드 | The use of an anti-allergy agent and a steroid to treat allergic rhinitis |
-
2003
- 2003-08-29 ES ES10167527T patent/ES2393864T3/en not_active Expired - Lifetime
- 2003-08-29 NZ NZ538954A patent/NZ538954A/en not_active IP Right Cessation
- 2003-08-29 ES ES03755551T patent/ES2348034T3/en not_active Expired - Lifetime
- 2003-08-29 BR BR0313611-6A patent/BR0313611A/en not_active IP Right Cessation
- 2003-08-29 DK DK03755551.3T patent/DK1545548T3/en active
- 2003-08-29 EP EP10167527A patent/EP2295062B1/en not_active Expired - Lifetime
- 2003-08-29 WO PCT/EP2003/009622 patent/WO2004019955A1/en active Application Filing
- 2003-08-29 CA CA2495830A patent/CA2495830C/en not_active Expired - Fee Related
- 2003-08-29 US US10/524,821 patent/US7879832B2/en active Active
- 2003-08-29 AU AU2003273396A patent/AU2003273396B2/en not_active Expired
- 2003-08-29 MX MXPA05001885A patent/MXPA05001885A/en active IP Right Grant
- 2003-08-29 PL PL03373433A patent/PL373433A1/en not_active Application Discontinuation
- 2003-08-29 SI SI200331870T patent/SI1545548T1/en unknown
- 2003-08-29 JP JP2004532150A patent/JP4746318B2/en not_active Expired - Lifetime
- 2003-08-29 AT AT03755551T patent/ATE472329T1/en active
- 2003-08-29 EP EP03755551A patent/EP1545548B1/en not_active Expired - Lifetime
- 2003-08-29 PT PT03755551T patent/PT1545548E/en unknown
- 2003-08-29 DE DE60333205T patent/DE60333205D1/en not_active Expired - Lifetime
- 2003-08-29 CN CNA038198606A patent/CN1674916A/en active Pending
- 2003-08-29 BR BRPI0313611-6A patent/BRPI0313611B1/en unknown
- 2003-08-29 KR KR1020057002903A patent/KR101067795B1/en active IP Right Grant
-
2005
- 2005-01-25 ZA ZA200500719A patent/ZA200500719B/en unknown
- 2005-01-25 IL IL166483A patent/IL166483A/en active IP Right Grant
- 2005-03-22 NO NO20051521A patent/NO335400B1/en not_active IP Right Cessation
-
2010
- 2010-11-05 JP JP2010248760A patent/JP2011021043A/en active Pending
- 2010-12-20 US US12/973,414 patent/US8486923B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2495830A1 (en) | The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis | |
| AU701292B2 (en) | Antipsychotic treatment | |
| SK285587B6 (en) | Use of CGRP antagonists and CGRP release inhibitors | |
| CA2478612C (en) | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | |
| EP0730865A1 (en) | Use of serotonin and dopamine receptor blockers for the treatment of mental disorders associated with cerebrovascular disease | |
| US20040023951A1 (en) | Combination therapy for treatment of psychoses | |
| MXPA01009787A (en) | Combination, for treating depression and anxiety, containing an nk-3 receptor antagonist and a cns penetrant nk-1 receptor antagonist. | |
| CA2411386A1 (en) | Combination therapy for treatment of psychoses | |
| WO2023034466A1 (en) | Cgrp antagonists for treating psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |
|
| MKLA | Lapsed |
Effective date: 20190829 |